Insuman Infusat (Insulin Human)

Insulin human binds to insulin receptors on cell surfaces, activating intracellular pathways that promote the movement of glucose transporters to the cell membrane. This increases glucose uptake into muscle and fat cells and suppresses glucose production by the liver, resulting in reduced blood glucose concentrations.

The dose of Insuman Infusat is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood glucose readings, body weight, diet, activity level, and overall treatment plan. Patients should follow the prescribing clinician’s instructions and adjust only under medical guidance.

Insulin human is classified as a pregnancy category that may be used when the potential benefit justifies the potential risk to the fetus. It is generally considered safe for use in pregnancy and lactation because insulin does not cross the placenta in significant amounts, but treatment decisions should be made by a healthcare professional.

To request Insuman Infusat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Insuman Infusat contains recombinant human insulin, which has a molecular structure identical to endogenous insulin. Compared with insulin analogues, it may have a shorter duration of action and a different onset profile. Choice of product depends on clinical goals, dosing convenience, and individual patient response as assessed by the prescribing clinician.

Insuman Infusat should be stored in a refrigerator at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Once in use, the product may be kept at controlled room temperature (up to 25 °C) for a limited period, as indicated on the label.

Insuman Infusat is administered by subcutaneous injection into the abdomen, thigh, or upper arm. The injection technique, site rotation, and dosing schedule should follow the prescriber’s instructions and standard insulin administration guidelines to ensure optimal absorption and minimize injection‑site complications.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local irritation to anaphylaxis. Patients should be educated on recognizing early signs of low blood sugar and on steps to take in case of a suspected allergic response.

Insuman Infusat should be avoided in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia until glucose levels are corrected. Clinicians must assess each patient’s medical history before initiating therapy.